Mavacamten

heart surgery catheter hospital surgeon
Clinical Data

Bristol Myers drug helps patients avoid heart procedures

Bristol Myers is presenting data that shows its targeted heart drug mavacamten helped reduce the risk of needing septal reduction therapy.
Annalee Armstrong Apr 2, 2022 9:30am
Stop watch

BMS heart drug delayed as risk mitigation program worked out

Nov 19, 2021 8:55am
Bristol Myers Squibb new sign outside

BMS' $13B MyoKardia heart drug gets along with beta blockers

Nov 13, 2021 8:00am
Bristol Myers Squibb new sign outside

BMS unveils more mavacamten data, nabbed in $13B MyoKardia deal

May 15, 2021 12:15pm
handshake

Bristol Myers strikes $13B MyoKardia buyout to gain heart drug

Oct 5, 2020 8:10am
heart model

MyoKardia's mavacamten boosts heart function in phase 3 study

Aug 29, 2020 1:10pm